Home » Stocks » REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Stock Price: $517.70 USD -6.03 (-1.15%)
Updated May 18, 2021 1:16 PM EDT - Market open
Market Cap 55.80B
Revenue (ttm) 9.20B
Net Income (ttm) 4.00B
Shares Out 105.40M
EPS (ttm) 35.13
PE Ratio 14.74
Forward PE 11.59
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $517.70
Previous Close $523.73
Change ($) -6.03
Change (%) -1.15%
Day's Open 523.00
Day's Range 513.68 - 526.96
Day's Volume 370,440
52-Week Range 441.00 - 664.64


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Stocks that soar or plunge get all the attention.

1 day ago - GuruFocus

TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/ --  Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo Similar efficacy observed w...

1 day ago - PRNewsWire

Pivotal d ata at ATS 2021 s how Dupixent ® (dupilumab) s ignificantly r educed a sthma a ttacks and i mproved l ung f unction in c hildren

1 day ago - GlobeNewsWire

TARRYTOWN, N.Y. and PARIS, May 17, 2021 /PRNewswire/ --  Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a r...

1 day ago - PRNewsWire

TARRYTOWN, N.Y. and PARIS, May 12, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free surv...

5 days ago - PRNewsWire

In my opinion, picking U.S.-listed equities that have the following characteristics represents a solid starting point when looking for potential value opportunities:

Other stocks mentioned: HUM, VALE
1 week ago - GuruFocus

It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.

Other stocks mentioned: BEAM, EXAS, MRNA, NTLA, XBI
1 week ago - The Motley Fool

Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

1 week ago - Zacks Investment Research

The big biotech delivered impressive revenue and earnings growth.

1 week ago - The Motley Fool

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are rising on the company's upbeat first-quarter earnings report, which boasted a rise in profits to $9.89 per share -- toppling analysts' estim...

1 week ago - Schaeffers Research

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of $2.56 billion.

1 week ago - Benzinga

Regeneron (REGN) delivered earnings and revenue surprises of 12.51% and -1.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Regeneron Pharmaceuticals Inc reported a 78% rise in first-quarter profit on Thursday, helped by a robust recovery in demand for its eye drug Eylea.

1 week ago - Reuters

TARRYTOWN, N.Y., May 6, 2021 /PRNewswire/ -- First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) increased 20% First quarter 2021 EYL...

1 week ago - PRNewsWire

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

1 week ago - Zacks Investment Research

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for treatment of COVID-19. Cipla will partner f...

Other stocks mentioned: RHHBY
1 week ago - Benzinga

Tom Gayner (Trades, Portfolio), chief investment officer of Markel Corp. ( MKL , Financial), disclosed this week that his firm's top five trades during the first quarter included a new buy in Regeneron ...

Other stocks mentioned: EFX, IFF, MCHP, MKL, OI
1 week ago - GuruFocus

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.

2 weeks ago - Zacks Investment Research

TARRYTOWN, N.Y., May 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive Phase 3 data from trials evaluating two Regeneron medicines will be featured at ...

2 weeks ago - PRNewsWire

In the latest trading session, Regeneron (REGN) closed at $485, marking a -0.57% move from the previous day.

2 weeks ago - Zacks Investment Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

A new delivery method for its COVID-19 treatment may offer a boost.

2 weeks ago - The Motley Fool

The stock market is at all-time highs, and the world is starting to reopen. But these healthcare stocks have more growth opportunities ahead.

Other stocks mentioned: BNTX, DGX, GILD, MRK, TDOC, UHS
3 weeks ago - InvestorPlace

Major gains may be on the horizon.

Other stocks mentioned: GRTS, PFE
3 weeks ago - The Motley Fool

In the latest trading session, Regeneron (REGN) closed at $488.64, marking a -0.36% move from the previous day.

3 weeks ago - Zacks Investment Research

TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference...

3 weeks ago - PRNewsWire

TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ --  Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement i...

3 weeks ago - PRNewsWire

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other stocks mentioned: AMGN, BMY, REPL, RHHBY, SNY
3 weeks ago - GuruFocus

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 weeks ago - Zacks Investment Research

You don't need to pay a big premium for these buy-and-hold investments.

Other stocks mentioned: BIDU, PCAR
3 weeks ago - The Motley Fool

The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.

3 weeks ago - The Motley Fool

Over the past few months we have maintained our view that Regeneron stock looks undervalued. The stock has largely been in focus since last year amid the development of REGEN-COV, its Covid-19 antibody ...

4 weeks ago - Forbes

They're among the top 10 holdings in one of Ark Invest's biggest funds.

Other stocks mentioned: TDOC, VRTX
1 month ago - The Motley Fool

And they all have one key thing in common.

Other stocks mentioned: VRTX, TDOC, TWST
1 month ago - The Motley Fool

"I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.

Other stocks mentioned: GSK, JNJ, LLY, UNH
1 month ago - CNBC

Regeneron's antibody drug offers strong protection against Covid-19

YouTube video

A new study shows Regeneron's antibody cocktail can offer strong protection against Covid-19, but Regeneron's antibody cocktail still needs FDA approval for the drug to be used for preventative use. Meg...

1 month ago - CNBC Television

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appe...

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE
1 month ago - InvestorPlace

Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.

1 month ago - Zacks Investment Research

Regeneron CEO on FDA request for expanded EUA of Covid antibody drug

YouTube video

Regeneron Pharmaceuticals said Monday it will ask the Food and Drug Administration to allow its Covid-19 antibody therapy to be used as a preventative treatment. Regeneron CEO Leonard Schleifer joined "...

1 month ago - CNBC Television

TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic...

1 month ago - PRNewsWire

Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%.

1 month ago - CNBC

TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ --  REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week,...

1 month ago - PRNewsWire

EBay Inc (NASDAQ: EBAY), SunPower Corporation (NASDAQ: SPWR), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Tupperware Brands Corporation (NYSE: TUP) are four stocks considered technically undervalue...

Other stocks mentioned: EBAY, SPWR, TUP
1 month ago - Benzinga

TARRYTOWN, N.Y., April 9, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongl...

1 month ago - PRNewsWire

These big biotechs check off all the boxes.

Other stocks mentioned: MRNA, VRTX
1 month ago - The Motley Fool

TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2021 financial and operating results on Thursday, May ...

1 month ago - PRNewsWire

Investors need to hold the best companies that money can buy on the Nasdaq, amid a growing weakness in the technology stock index. The post 7 Best Stocks on the Nasdaq appeared first on InvestorPlace.

Other stocks mentioned: CSCO, DLTR, DOCU, FB, INTC, MSFT
1 month ago - InvestorPlace

Their growth prospects are too good to ignore.

Other stocks mentioned: PINS, PYPL
1 month ago - The Motley Fool

There are a couple of obstacles that could get in the way.

1 month ago - The Motley Fool

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent i... [Read more...]

IPO Date
Apr 2, 1991
Leonard Schleifer
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, REGN's revenue was $8.50 billion, an increase of 29.58% compared to the previous year's $6.56 billion. Earnings were $3.51 billion, an increase of 66.05%.

Financial Statements

Analyst Forecasts

According to 27 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 628.36, which is an increase of 21.38% from the latest price.

Price Target
(21.38% upside)
Analyst Consensus: Buy